Boldly investing in
exceptional people
breakthrough medicine
better outcomes for patients
Built by seasoned investors, operators and entrepreneurs we form a generational investing firm that knows what it takes to deliver for patients and investors.
>0
FDA approved medicines
>$0B
Capital raised
>0
IPOs transacted
0
M&A exits >$1B
A team built to deliver
Leadership
Team
Science Partners
Our approach
Access
Our relationships and reputations have been built over decades. Together, we have unparalleled access to biomedical breakthroughs and bold innovators with whom we partner.
Analysis
As open-minded truth seekers, we apply analytical rigor through a collaborative process, building fundamental conviction to support our decision-making.
Action
We are doers who bring entrepreneurial drive and operational experience to the table. With a track record of integrity and follow-through, we seek to be a trusted partner of choice to teams changing the world.
Alignment
Our values, strategy and conduct are in harmony. When we win, we win together for patients, communities, and our investors.
Patient Impact
Patients are our North Star. With a sense of urgency and purpose, we drive to get life changing medicines into their hands.
Value Creation
Our investors are our long-term partners. We build and back outstanding companies to deliver outsized returns.
Decades
of turning ideas
into impact
for patients
Developed by Revolution Medicines
FDA approved in 2026
Investor Jakob Loven
Developed by CymaBay Therapeutics
FDA approved in 2024
CEO / CFO Sujal Shah
CSO / SVP R&D Chuck McWherter
VP Corporate Comms Arran Attridge
Developed by Peloton Therapeutics
FDA approved in 2021 (VHL) and 2023 (RCC)
Investor Stefan Vitorovic
Developed by Praxis Precision Medicines
Relutrigine PDUFA Dec 2026
Ulixacaltamide PDUFA Jan 2027
Director and Founding Investor Stefan Vitorovic
Developed by Decibel Therapeutics
FDA approved in 2026
Founding team member and investor Stefan Vitorovic
Developed by Merck
First FDA approval in 2014
Program Development Team led by Alise Reicin
Discovered and developed by Relay Therapeutics
commercialized by Elevar Therapeutics
FDA approved in 2026
Founding CSO and current Board Director Mark Murcko
Founding team member and investor Jakob Loven
Developed by Eisai and Biogen
FDA approved in 2021 & 2023
SVP and Head Neurodegeneration Development
Samantha Budd Haeberlein
Developed by Plexxikon / Roche
FDA approved in 2011
Clinical development led by Keith Flaherty
Developed by Agouron
FDA approved in 1997
Development led by Mike Varney
Together, we can turn ambitious ideas into the next generation of medical breakthroughs.
